Get the free Draft Guidance on Zalcitabine - fda
Show details
This document provides draft guidance from the FDA regarding the active ingredient Zalcitabine, detailing required studies and testing for bioequivalence.
We are not affiliated with any brand or entity on this form
Get, Create, Make and Sign draft guidance on zalcitabine
Edit your draft guidance on zalcitabine form online
Type text, complete fillable fields, insert images, highlight or blackout data for discretion, add comments, and more.
Add your legally-binding signature
Draw or type your signature, upload a signature image, or capture it with your digital camera.
Share your form instantly
Email, fax, or share your draft guidance on zalcitabine form via URL. You can also download, print, or export forms to your preferred cloud storage service.
Editing draft guidance on zalcitabine online
Follow the guidelines below to benefit from the PDF editor's expertise:
1
Log in to account. Start Free Trial and register a profile if you don't have one yet.
2
Simply add a document. Select Add New from your Dashboard and import a file into the system by uploading it from your device or importing it via the cloud, online, or internal mail. Then click Begin editing.
3
Edit draft guidance on zalcitabine. Add and change text, add new objects, move pages, add watermarks and page numbers, and more. Then click Done when you're done editing and go to the Documents tab to merge or split the file. If you want to lock or unlock the file, click the lock or unlock button.
4
Save your file. Select it from your records list. Then, click the right toolbar and select one of the various exporting options: save in numerous formats, download as PDF, email, or cloud.
It's easier to work with documents with pdfFiller than you could have believed. Sign up for a free account to view.
Uncompromising security for your PDF editing and eSignature needs
Your private information is safe with pdfFiller. We employ end-to-end encryption, secure cloud storage, and advanced access control to protect your documents and maintain regulatory compliance.
How to fill out draft guidance on zalcitabine
How to fill out Draft Guidance on Zalcitabine
01
Read the title and introduction of the Draft Guidance on Zalcitabine to understand its purpose.
02
Review the sections outlining the indications for Zalcitabine treatment.
03
Follow the instructions for dosage and administration as outlined in the guidance.
04
Check the contraindications and precautions that need to be considered.
05
Look for sections detailing potential side effects and monitoring requirements.
06
Complete any required forms or documents as specified in the guidance.
07
Submit the completed documentation to the appropriate regulatory authority or organization.
Who needs Draft Guidance on Zalcitabine?
01
Healthcare professionals involved in the prescribing and management of Zalcitabine treatment.
02
Researchers conducting studies related to Zalcitabine.
03
Pharmacists responsible for dispensing Zalcitabine.
04
Patients receiving Zalcitabine therapy and their caregivers for better understanding.
Fill
form
: Try Risk Free
People Also Ask about
What are the side effects of Zalcitabine?
Side effects include seizures, lactic acidosis, thrombocytopenia, leukopenia, anemia, eosinophilia, peripheral neuropathy, hepatic dysfunction, fatigue, N/V, abdominal pain, diarrhea, constipation, rash, pruritus, urticaria, oral lesions, depression, headache, fever, cough, and rhinitis.
What drug category is zalcitabine?
Zalcitabine is a pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase. It has a role as an antiviral drug, an antimetabolite and a HIV-1 reverse transcriptase inhibitor.
What is the half life of Zalcitabine?
Half-life: 1-3 hr; metabolite, 2.6-10 hr (increased in impaired renal function). Available Forms: Tablets: 0.375 mg, 0.75 mg.
What class of drugs is Zalcitabine?
Zalcitabine is an oral medication that is used for the treatment of infections with the human immunodeficiency virus (HIV). It is in a class of drugs called reverse transcriptase inhibitors, which also includes lamivudine (Epivir), zidovudine (Retrovir), didanosine (Videx), and stavudine (Zerit).
Is Zalcitabine still used?
General information. Zalcitabine (dideoxycytidine, DDC) is a nucleoside analogue reverse transcriptase inhibitor. Because of the high incidence of nervous system adverse effects and the availability of less toxic alternatives, zalcitabine is no longer used.
What class of drug is Ritonavir?
Ritonavir is in a class of medications called protease inhibitors. It works by decreasing the amount of HIV in the blood. Although ritonavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer.
What is the drug Zalcitabine used for?
Zalcitabine is a potent nucleoside analogue inhibitor of reverse transcriptase used in the treatment of HIV infection. It is approximately 10-fold more potent than zidovudine (AZT) on a molar basis in vitro. Zalcitabine is well absorbed orally and reaches maximal plasma concentrations within 1 to 2 hours.
Is Zalcitabine still used?
General information. Zalcitabine (dideoxycytidine, DDC) is a nucleoside analogue reverse transcriptase inhibitor. Because of the high incidence of nervous system adverse effects and the availability of less toxic alternatives, zalcitabine is no longer used.
For pdfFiller’s FAQs
Below is a list of the most common customer questions. If you can’t find an answer to your question, please don’t hesitate to reach out to us.
What is Draft Guidance on Zalcitabine?
Draft Guidance on Zalcitabine refers to a set of recommendations and protocols provided by regulatory authorities that outline the necessary information, procedures, and standards for the use and approval of Zalcitabine, an antiretroviral medication used in the treatment of HIV.
Who is required to file Draft Guidance on Zalcitabine?
Pharmaceutical companies and researchers developing Zalcitabine or any related applications are required to file Draft Guidance on Zalcitabine. This includes those seeking approval to market the drug or conduct clinical trials.
How to fill out Draft Guidance on Zalcitabine?
To fill out Draft Guidance on Zalcitabine, applicants must adhere to the specific format outlined in the guidance document, providing detailed information about the drug's development, clinical data, manufacturing processes, labeling, and compliance with regulatory standards.
What is the purpose of Draft Guidance on Zalcitabine?
The purpose of Draft Guidance on Zalcitabine is to provide a clear framework for submitting data and information required for the assessment of the drug's safety, efficacy, and quality by regulatory authorities.
What information must be reported on Draft Guidance on Zalcitabine?
Information that must be reported includes detailed results from clinical trials, preclinical studies, pharmacology data, manufacturing processes, quality control measures, product labeling, and any potential side effects or risks associated with the use of Zalcitabine.
Fill out your draft guidance on zalcitabine online with pdfFiller!
pdfFiller is an end-to-end solution for managing, creating, and editing documents and forms in the cloud. Save time and hassle by preparing your tax forms online.
Draft Guidance On Zalcitabine is not the form you're looking for?Search for another form here.
Relevant keywords
If you believe that this page should be taken down, please follow our DMCA take down process
here
.
This form may include fields for payment information. Data entered in these fields is not covered by PCI DSS compliance.
